Lee Pitcher MP: written questions

94 published records · newest first.

Written questions

Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9219More
Question: To ask the Secretary of State for Health and Social Care, what information his Department holds on (a) the likelihood of patients who develop one dopamine agonist-associated impulse control disorder developing additional impulse control disorders and (b)
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record
Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9217More
Question: To ask the Secretary of State for Health and Social Care, what data the Department holds on the proportion of patients with restless legs syndrome alone, compared with patients with restless legs syndrome and attention deficit hyperactivity disorder, auti
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record
Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9216More
Question: To ask the Secretary of State for Health and Social Care, what data the Department holds on the proportion of patients with restless legs syndrome treated with dopamine agonists who have co-existing neurodevelopmental or psychiatric diagnoses, including a
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record
Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9215More
Question: To ask the Secretary of State for Health and Social Care, what assessment the Department has made of risk factors for dopamine agonist-induced impulse control disorders, including age, renal impairment, duration of exposure, cumulative dose, polypharmacy,
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record
Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9214More
Question: To ask the Secretary of State for Health and Social Care, what data the Department holds on the average age at (a) initiation of dopamine agonist therapy, (b) first report or diagnosis of an impulse control disorder while taking a dopamine agonist and (c)
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record
Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9213More
Question: To ask the Secretary of State for Health and Social Care, what data the Department holds on (a) the average length of time patients remain on dopamine agonists or partial dopamine agonists for each licensed indication, (b) the proportion of patients who r
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record
Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9212More
Question: To ask the Secretary of State for Health and Social Care, what information national pharmacovigilance systems and clinical datasets provide on the range and relative frequency of withdrawal symptoms associated with dopamine agonist discontinuation, includ
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record
Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9211More
Question: To ask the Secretary of State for Health and Social Care, what evidence the Department has assessed on the average time from initiating a dopamine agonist, or increasing its dose, to (a) the onset or first report of impulse control disorder symptoms and (
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record
Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9210More
Question: To ask the Secretary of State for Health and Social Care, what evidence the Department has assessed on the number and proportion of patients who develop impulse control disorders while taking dopamine agonists and subsequently (a) continue dopamine agonis
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record
Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9209More
Question: To ask the Secretary of State for Health and Social Care, what data national bodies hold on (a) the number and proportion of people prescribed dopamine agonists who self-report impulse control disorders and (b) the number and proportion whose impulse cont
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record
Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9208More
Question: To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the use of artificial intelligence and digital tools within the NHS and the Medicines and Healthcare products Regulatory Agency to (a) detect potential do
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record
Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9207More
Question: To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the effectiveness of how dopamine agonist-related impulse control disorders and augmentation are taught and assessed in undergraduate medical educat
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record
Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9206More
Question: To ask the Secretary of State for Health and Social Care, whether his Department holds audit or research data on differences between neurology or movement disorder specialists and general practitioners in (a) warning patients and families about dopamine a
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record
Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9205More
Question: To ask the Secretary of State for Health and Social Care, what guidance is issued to clinicians on discussing in advance with patients, and where appropriate their families, how treatment should be managed if severe impulse control disorders develop while
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record
Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9204More
Question: To ask the Secretary of State for Health and Social Care, what assessment the Department has made of the levels of (a) sexually transmitted infections acquired in the context of dopamine agonist-induced hypersexuality and (b) unplanned pregnancies among w
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record
Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9203More
Question: To ask the Secretary of State for Health and Social Care, what data the Department holds on (a) the number and proportion of dopamine agonist-treated patients who report binge eating or marked weight gain, (b) weight and metabolic monitoring practices whe
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record
Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9202More
Question: To ask the Secretary of State for Health and Social Care, what assessment the Department has made of the level of suicides and attempted suicides among (a) people prescribed dopamine agonists who have experienced impulse control disorders, augmentation or
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record
Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9201More
Question: To ask the Secretary of State for Health and Social Care, what data the Department holds on the number and proportion of dopamine agonist-treated patients with impulse control disorders who experience relationship breakdown or divorce.
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record
Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9200More
Question: To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of dopamine agonist-related impulse control disorders and augmentation in people with restless legs syndrome and Parkinson’s disease
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record
Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9199More
Question: To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential financial impact of dopamine agonist-related impulse control disorders on those experiencing such disorders, including through (a) gambling-
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record
Drugs: Side EffectsDepartment of Health and Social CareTabled 10 Jun 2026AnsweredUIN 8940More
Question: To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number and proportion of patients who, having developed impulse control disorders while taking dopamine agonists and attempted withdrawal, subsequently
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record
Drugs: Side EffectsDepartment of Health and Social CareTabled 10 Jun 2026AnsweredUIN 8939More
Question: To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the typical duration and severity of withdrawal symptoms associated with dopamine agonist dose reduction or discontinuation; and how those outcomes vary b
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record
Drugs: Side EffectsDepartment of Health and Social CareTabled 10 Jun 2026AnsweredUIN 8938More
Question: To ask the Secretary of State for Health and Social Care, what data his Department and the Medicines and Healthcare products Regulatory Agency holds on how many and what proportion of patients develop withdrawal symptoms, including dopamine agonist withdr
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record
Drugs: Side EffectsDepartment of Health and Social CareTabled 10 Jun 2026AnsweredUIN 8937More
Question: To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the extent of under-reporting of dopamine agonist-related impulse control disorders to the Yellow Card scheme; and what steps it is taking to improv
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record
Drugs: Side EffectsDepartment of Health and Social CareTabled 10 Jun 2026AnsweredUIN 8936More
Question: To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of patients exposed to dopamine agonists for (a) Parkinson’s disease and (b) restless legs syndrome; and what comparison the Department has made
Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Answered 8 Jul 2026
Original Parliament record

Published records only — not a full account of an MP’s work. How we work →